Actelion Pharmaceuticals

Actelion is a Swiss biopharmaceutical company with several products on the market, primarily focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri, treating different stages of the disease through various administration methods. Zavesca is a second-line treatment for Gaucher's disease, and Valchlor treats a rare type of blood cancer. Actelion has established global commercial infrastructure for its approved orphan drugs and supplemented its internal pipeline through licensing and acquisitions.